News
(2)April 2026
CRVO data show neflamapimod reverses DLB brain atrophy and improves function
# 📄 What This Document Is 📰 This filing is a press release announcing significant new scientific data presented by CervoMed Inc. (NASDAQ: CRVO) at the 2026 AAN Annual Meeting in Chicago. This document details the results from the RewinD-LB Phase 2b clinical trial, focusing on the drug neflamapimod
CervoMed Inc. — 8-K Filing
# 📢 What This Document Is This is an 8-K filing, which is like a company's official "news flash" to the stock market. CervoMed is using it to announce that it will be presenting major updates about its key drug, neflamapimod, at important medical conferences. It's a way to build credibility and sha
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.